Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 – The Liver Meeting® and Attendance at November Conferences
Barinthus Biotherapeutics plc - American Depositary Shares (BRNS)
Company Research
Source: GlobeNewswire
OXFORD, United Kingdom, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease, today announced that updated clinical data from its chronic hepatitis B program will be highlighted as a late breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2024 being held November 15-19, 2024 in San Diego, California and attendance at multiple conferences in November: Medical Congresses AASLD – The Liver Meeting® 2024: Late breaking abstract accepted as oral presentation.Title: VTP-300 combined with low-dose nivolumab is associated with HBsAg loss in certain chronic hepatitis B participants with HBsAg less than 200 IU/mL: Results from a phase 2b open-label study. International Workshop on HBV Cure 2024: Formal presentation titled “HBsAg Levels and T Cell Boost in Patients with HBs
Show less
Read more
Impact Snapshot
Event Time:
BRNS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BRNS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BRNS alerts
High impacting Barinthus Biotherapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BRNS
News
- Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb SeroconversionGlobeNewswire
- Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis BGlobeNewswire
- Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.MarketBeat
- Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial ResultsGlobeNewswire